Latest filing published 28 Feb 2023 for National Research CORP, €310k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Kevin R. Karas: trading record in brief
Kevin R. Karas (finance chief) discloses dealings in NRC Health to SEC (Form 4). Between 5 January 2016 and 28 February 2023, the trades on record add up to 29 filings.
Every open-market trade on record is a sale: 15 sales worth €2.5M. The rest of the record consists of 8 share grants and 4 option exercises. So far in 2023, the count stands at no purchases and 3 sales.
On 28 February 2023 came the latest disclosure, an open-market sale for €105k in NRC Health. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Kevin R. Karas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,156 shares@ US$45.842440.6% of flowCommon StockSEC:0001567619-23-003958:0
- 5,000 shares@ US$53.16342.2% of flowCommon StockSEC:0001567619-21-015064:0
- 7,087 sharesClass A Common StockSEC:0001140361-16-047156:0
- 1,127 sharesClass B Common StockSEC:0001140361-16-047156:1
4 of 4 declarations
